The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited. (Q53438701)

http://europepmc.org/abstract/PMC/5304393

14 May 2018

title

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited. (English)

1 reference

http://europepmc.org/abstract/PMC/5304393

14 May 2018

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Melissa M Brown

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

Heidi B Lieske

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

Adam Turpcu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

Yamina Rajput

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

publication date

13 February 2017

1 reference

http://europepmc.org/abstract/PMC/5304393

14 May 2018

published in

International Journal of Retina and Vitreous

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Ranibizumab for neovascular age-related macular degeneration

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Prevalence of age-related macular degeneration in the United States

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Utilities associated with diabetic retinopathy: results from a Canadian sample

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Quality of life and systemic comorbidities in patients with ophthalmic disease

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

The reproducibility of ophthalmic utility values

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Utility values associated with blindness in an adult population

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Vision and quality-of-life

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

A value analysis model applied to the management of amblyopia.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Cataract surgery cost utility revisited in 2012: a new economic paradigm

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Utility values and age-related macular degeneration.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5304393

Computerized model of cost-utility analysis for treatment of age-related macular degeneration

13 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186/S40942-016-0058-3

Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186/S40942-016-0058-3

Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186/S40942-016-0058-3

Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots

21 January 2018

1 reference

12 December 2020

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration

1 reference

12 December 2020

Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen

1 reference

12 December 2020

Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden

1 reference

12 December 2020

10.1186/S40942-016-0058-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28289548 AND SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

28289548

1 reference